A Phase 2 interventional study of Panitumumab and Cisplatin in Cancer, Head and Neck Cancer and Oncology, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN). A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.
Primary Objective: To estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN).
Secondary Objectives: To estimate the difference between 2 treatment regimens (CRT vs PRT) on other measures of clinical benefit, including LRC, overall response rate (ORR), progression-free survival (PFS), overall survival (OS); and safety.
Tertiary Objectives: To estimate the difference in health-related quality of life (HRQoL) and performance status in subjects receiving PRT or CRT.
Exploratory Objectives: To investigate potential biomarker development based on assessment of blood and tumor and the proposed mechanism of actions of study drugs. In addition, to investigate the effect of genetic variation in cancer genes and drug target genes on SCCHN and subject response to study drugs (separate informed consent required).
Hypothesis: A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.
Study Design: This is a phase 2, open-label, randomized, multicenter study. Eligible subjects will be randomized in a 2:3 ratio to either of the following regimens:
Arm 1 CRT:
Arm 2 PRT:
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 152 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed SCC of the oral cavity, oropharynx, hypopharynx or larynx Stage III or Stage IVa-b (M0) disease according to the American Joint Committee on Cancer staging manual 6th edition (locally advanced) performance status of 0 or 1 Bidimensionally >/= 10 mm in at least 1 dimension
Exclusion Criteria:
NO Primary tumor of the nasopharynx, sinuses, salivary gland, or skin NO Subjects requiring prophylactic tracheostomy NO Prior (or concomitant) (except non-melanomatous skin cancer or in situ cervical cancer), other than the study disease (SCCHN), unless treated with curative intent with no evidence of disease for >/= 3 years NO Prior treatment for locally advanced SSCHN NO Prior surgery for SCCHN (except nodal sampling or for study disease) NO Major surgery \</= 28 days before randomization or minor surgery \</= 14 days before randomization with the exception of feeding tube placement, dental extractions, central venous catheter placement, biopsies and nodal sampling
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cisplatin plus RT
Drug: Cisplatin
Panitumumab plus RT
Drug: Panitumumab
Arm 2 consists of panitmumab plus RT
Also known as: Panitumumab (drug)
Cisplatin
Also known as: Cisplatin (Chemotherapy)
Local Regional Control Rate at 2 Years
Kaplan-Meier estimate of Local regional control rate at 2 years. Local regional control rate will be measured according to the investigator's assessment of disease status based on all available data (ie, from clinical examination, radiologic assessments, pathology reports, and autopsy reports).
Time frame: from study day 1 to 2 years
Duration of Local Regional Control
Time from study day 1 to the date of first local-regional failure or to death due to any cause (whichever occurs first)
Time frame: maximum follow up time 46.2 months
Progression-free Survival
Time from first dose date till disease progression or death
Time frame: maximum follow up time 46.2 months
Overall Survival
Time from first dose date to death
Time frame: maximum follow up time 46.2 months
ORR by 6 Months - Central
ORR is Objective Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete or partial response is considered as objective response.
Time frame: From randomization to 6 months
CRR by 6 Months - Central
CRR is Complete Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete Response (CR) is defined as disappearance of all index lesions.
Time frame: From randomization till 6 months
152 subjects were enrolled with 90 subjects randomized to panitumumab plus radiotherapy arm, and 62 subjects randomized to chemoradiotherapy arm.
| Milestone | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| Started | 90 | 62 |
| Completed | 41 | 39 |
| Not completed | 49 | 23 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Death | 38 | 18 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Administrative decision | 3 | 2 |
| Withdrew: Lost to follow-up | 4 | 2 |
Kaplan-Meier estimate of Local regional control rate at 2 years. Local regional control rate will be measured according to the investigator's assessment of disease status based on all available data (ie, from clinical examination, radiologic assessments, pathology reports, and autopsy reports).
| Proportion of Participants | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| Local Regional Control Rate at 2 Years | 0.51 (0.40 to 0.62) | 0.61 (0.47 to 0.72) |
Time from study day 1 to the date of first local-regional failure or to death due to any cause (whichever occurs first)
| months | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| Duration of Local Regional Control | 25.1 (12.0 to 36.0) | NA (14.4 to NA) |
Time from first dose date till disease progression or death
| months | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| Progression-free Survival | 17.3 (12.0 to 27.0) | NA (17.5 to NA) |
Time from first dose date to death
| months | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| Overall Survival | 41.7 (27.2 to NA) | NA (NA to NA) |
ORR is Objective Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete or partial response is considered as objective response.
| Proporation of Participants | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| ORR by 6 Months - Central | 0.722 (0.618 to 0.812) | 0.767 (0.640 to 0.866) |
CRR is Complete Response Rate. Tumor assessments are based on central review of scans uisng a modification of the WHO criteria. Complete Response (CR) is defined as disappearance of all index lesions.
| Proportion of Participants | Panitumumab Plus Radiotherapy | Chemoradiotherapy |
|---|---|---|
| CRR by 6 Months - Central | 0.144 (0.079 to 0.234) | 0.117 (0.048 to 0.226) |
Collected over The median reporting period was around 74 days in the Panitumumab Plus Radiotherapy arm, and around 74 days in the Chemoradiotherapy arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus Radiotherapy | — | 30/89 (33.7%) | 88/89 (98.9%) |
| Chemotherapy Plus Radiotherapy | — | 25/62 (40.3%) | 61/62 (98.4%) |
| Event | Panitumumab Plus Radiotherapy | Chemotherapy Plus Radiotherapy |
|---|---|---|
| Mucosal inflammationGeneral disorders | 6/89 | 6/62 |
| DysphagiaGastrointestinal disorders | 7/89 | 3/62 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/89 | 4/62 |
| NeutropeniaBlood and lymphatic system disorders | 0/89 | 3/62 |
| Weight decreasedInvestigations | 3/89 | 0/62 |
| DehydrationMetabolism and nutrition disorders | 3/89 | 1/62 |
| StomatitisGastrointestinal disorders | 2/89 | 0/62 |
| Sudden deathGeneral disorders | 2/89 | 0/62 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/89 | 0/62 |
| Skin infectionInfections and infestations | 2/89 | 0/62 |
| Event | Panitumumab Plus Radiotherapy | Chemotherapy Plus Radiotherapy |
|---|---|---|
| DysphagiaGastrointestinal disorders | 64/89 | 39/62 |
| Mucosal inflammationGeneral disorders | 54/89 | 42/62 |
| Radiation skin injuryInjury, poisoning and procedural complications | 47/89 | 35/62 |
| RashSkin and subcutaneous tissue disorders | 48/89 | 2/62 |
| NauseaGastrointestinal disorders | 19/89 | 27/62 |
| OdynophagiaGastrointestinal disorders | 33/89 | 22/62 |
| Dry mouthGastrointestinal disorders | 30/89 | 21/62 |
| DysgeusiaNervous system disorders | 18/89 | 21/62 |
| ConstipationGastrointestinal disorders | 28/89 | 15/62 |
| VomitingGastrointestinal disorders | 14/89 | 18/62 |
| Age, Continuous(Years) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| Mean | 56.9 ± 8.3 | 57.4 ± 7.9 | 57.1 ± 8.1 |
| Sex: Female, Male(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| Female | 18 | 7 | 25 |
| Male | 72 | 55 | 127 |
| Race/Ethnicity, Customized(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| Asian | 0 | 00 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 88 | 60 | 148 |
| Hispanic or Latino | 2 | 2 | 4 |
| Radiotherapy Delivery Modality(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| IMRT | 49 | 32 | 81 |
| 3D-CRT | 41 | 29 | 70 |
| Missing | 0 | 1 | 1 |
| Primary Tumor Site(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| Oropharynx/Larynx | 66 | 44 | 110 |
| Oral Cavity/Hypopharynx | 24 | 18 | 42 |
| Nodal Status(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| N0 | 11 | 7 | 18 |
| N+ | 79 | 55 | 134 |
| Tumor Stage(Participants) | Panitumumab Plus Radiotherpy | Chemoradiotherapy | Total |
|---|---|---|---|
| T1-3 | 58 | 39 | 97 |
| T4 | 32 | 23 | 55 |
No study locations are listed for this record.
The record gives a start of Nov 2007, a primary completion of Dec 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab